Details of the Drug

General Information of Drug (ID: DMCK357)

Drug Name

Ribitol

Synonyms

xylitol; ribitol; adonitol; 488-81-3; 87-99-0; Xylite; D-Xylitol; Adonite; Adonit; D-ribitol; Xyliton; Eutrit; Klinit; Xylite (sugar); Kannit; Xylit; Newtol; 1,2,3,4,5-pentanepentol; Pentitol; (2R,3s,4S)-pentane-1,2,3,4,5-pentol; Fluorette; Xylisorb; Kylit; meso-ribitol; xylo-Pentitol; L-ribitol; (2R,3R,4S)-Pentane-1,2,3,4,5-pentaol; Xylitab 300; meso-xylitol; L-xylitol; D-Adonitol; Xylitol, d-; Xylitol cm 90; Ribitol (Adonitol); 16277-71-7; CHEBI:15963; CHEBI:17151; (2S,4R)-pentane-1,2,3,4,5-pentol; 1,2,3,4,5-Pentahydroxypentane; 2,3-DihydroAcrivastine; (2R,3r,4S)-pentane-1,2,3,4,5-pentol; xylo-Pentane-1,2,3,4,5-pentol; 2,3-Dihydro Acrivastine; C-xylidex cr 16055; 87849-01-2; 353ZQ9TVDA; VCQ006KQ1E; INS NO.967; Xylooligosaccharide; INS-967; MFCD00064291; MFCD00064292; NSC-25283; E-967; 4-01-00-02832 (Beilstein Handbook Reference); Adonitol;Adonite; EINECS 201-788-0; NSC 25283; UNII-353ZQ9TVDA; UNII-VCQ006KQ1E; DTXSID7042514; BRN 1720523; Adonito; Xylitol [INN:BAN:JAN:NF]; NSC-16868; DL-Arabinit; Xylitol C; HSDB 7967; Xylitab DC; (2R,3S,4S)-Pentane-1,2,3,4,5-pentaol; Wood sugar alcohol; RB0; Xylitol, Meso-xylitol, C-Xylidex CR 16055, DL-Xylitol, Eutrit, Fluorette, Klinit, Kylit, NSC 25283, Wood sugar alcohol, X 0018, Xylisorb, Xylisorb 300, Xylisorb 700, Xylit, Xylit XC, Xylitab 100, Xylitab 300, Xylitab DC, Xylite, Xylite (sugar), Xylitol C, Xylitol CM 90, Xylitol P, Xyliton, meso-Xylitol, xylo-Pentitol; Xylitol,(S); EINECS 207-685-7; Adonitol (7CI); Xylisorb 300; Xylisorb 700; NSC 16868; Xylitab 100; RIBO-PENTITOL; BRN 1720524; D-ribitol (incorrect); L-ribitol (incorrect); Adonitol, >=99%; (2R,4S)-pentane-1,2,3,4,5-pentol; XYLITOL [VANDF]; XYLITOL [INCI]; Xylitol, >=99%; ADONITOL [MI]; XYLITOL [FCC]; XYLITOL [JAN]; XYLITOL [II]; XYLITOL [MI]; XYLITOL [MART.]; XYLITOL [USP-RS]; XYLITOL [WHO-DD]; bmse000062; bmse000129; bmse000886; Epitope ID:114702; Epitope ID:114703; EC 201-788-0; SCHEMBL4250; Xylitol, analytical standard; SCHEMBL15318; MLS002695898; CHEMBL96783; Ribitol (6CI,8CI,9CI); XYLITOL [EP IMPURITY]; XYLITOL [EP MONOGRAPH]; QSPL 191; SCHEMBL1924966; CHEMBL1865120; CHEMBL3137744; DTXCID5022514; HEBKCHPVOIAQTA-NGQZWQHPSA-N; HEBKCHPVOIAQTA-SCDXWVJYSA-N; DTXSID601032335; HY-N0538; Tox21_201056; s2612; s4546; AKOS015903403; AKOS015915193; CCG-214167; CCG-266218; CS-6043; DB01904; DB11195; DB14704; CAS-87-99-0; NCGC00165982-01; NCGC00165982-02; NCGC00258609-01; NCGC00390798-01; Adonitol, BioXtra, >=99.0% (HPLC); AS-55964; DS-11416; E967; SMR001562099; HY-100582; Xylitol, Vetec(TM) reagent grade, >=99%; A0171; SW220290-1; X0018; A-3000; Adonitol, BioReagent, suitable for cell culture; C00379; C00474; X-7000; EN300-7377714; EN300-7424092; WURCS=2.0/1,1,0/[h212h]/1/; WURCS=2.0/1,1,0/[h222h]/1/; A842433; Q212093; Q416534; Xylitol, European Pharmacopoeia (EP) Reference Standard; Z1255486336; 5DCF4F57-E023-469A-B4F3-91E8349A6705; Xylitol, United States Pharmacopeia (USP) Reference Standard; 6684F574-C267-40CB-8828-12F2550E58D0; Xylitol, Pharmaceutical Secondary Standard; Certified Reference Material

Indication

Disease Entry	ICD 11	Status	REF
Limb-girdle muscular dystrophy	8C70.4	Phase 3	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C5H12O5
Canonical SMILES: C(C(C(C(CO)O)O)O)O
InChI: InChI=1S/C5H12O5/c6-1-3(8)5(10)4(9)2-7/h3-10H,1-2H2/t3-,4+,5?
InChIKey: HEBKCHPVOIAQTA-NGQZWQHPSA-N

Cross-matching ID

PubChem CID: 6912
UNII: VCQ006KQ1E
DrugBank ID: DB11195
TTD ID: D5LZO9

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

References

1	ClinicalTrials.gov (NCT05775848) A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I). U.S.National Institutes of Health.